Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash from Investing Activities (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Cash from Investing Activities for 12 consecutive years, with $5.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities rose 181.68% year-over-year to $5.1 million, compared with a TTM value of $16.5 million through Sep 2025, up 168.76%, and an annual FY2024 reading of $13.2 million, up 30.99% over the prior year.
  • Cash from Investing Activities was $5.1 million for Q3 2025 at Lisata Therapeutics, up from $505000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $12.3 million in Q3 2023 and bottomed at -$6.3 million in Q3 2024.
  • Average Cash from Investing Activities over 3 years is $3.5 million, with a median of $4.3 million recorded in 2023.
  • Peak annual rise in Cash from Investing Activities hit 1715.59% in 2024, while the deepest fall reached 151.46% in 2024.
  • Year by year, Cash from Investing Activities stood at -$5.7 million in 2023, then skyrocketed by 124.31% to $1.4 million in 2024, then soared by 270.77% to $5.1 million in 2025.
  • Business Quant data shows Cash from Investing Activities for LSTA at $5.1 million in Q3 2025, $505000.0 in Q2 2025, and $9.4 million in Q1 2025.